NEW YORK, January 10, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting ICU Medical, Inc. (NASDAQ: ICUI), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), and Array BioPharma Inc. (NASDAQ: ARRY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
ICU Medical, Inc. Research Report
On January 6, 2014, ICU Medical, Inc. (ICU Medical) announced that its management will participate at the 32nd Annual J.P. Morgan Healthcare Conference, to be held from January 13-16, 2014, at the Westin St. Francis Hotel in San Francisco, California. The Company informed that it is scheduled to make a presentation on January 16, 2014 at 10:30 a.m. PT, and a live webcast of the presentation along with its replay version can be accessed by interested parties via ICU Medical's website. The Full Research Report on ICU Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Integra LifeSciences Holdings Corporation Research Report
On December 30, 2013, Integra LifeSciences Holdings Corporation (Integra) announced its participation at the 32nd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, California. The Company informed that Integra President and CEO, Peter Arduini, is scheduled to make a presentation at the aforesaid conference on January 15, 2014 at 1:30 p.m. PT. According to the Company, interested parties can access a webcast of the presentation through Integra's website. The Full Research Report on Integra LifeSciences Holdings Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Taro Pharmaceutical Industries Ltd. Research Report
On December 30, 2013, Taro Pharmaceutical Industries Ltd. (Taro) announced the final results of its modified "Dutch auction" tender offer to repurchase up to $200 million in value of its ordinary shares, which expired on December 23, 2013. The Company informed that based on the final count by American Stock Transfer & Trust Company, LLC, the Depositary for the tender offer, an aggregate of 1.96 million ordinary shares were properly tendered and not properly withdrawn at or below the final purchase price of $97.50 per share. According to the Company, the dealer manager for the tender offer was J.P. Morgan Securities LLC, and the information agent was MacKenzie Partners Inc. The Full Research Report on Taro Pharmaceutical Industries Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
AMAG Pharmaceuticals, Inc. Research Report
On January 7, 2014, AMAG Pharmaceuticals, Inc. (AMAG) announced the appointment of Elizabeth Bolgiano to the position of Senior Vice President of Human Resources. The Company notified that prior to joining AMAG, Bolgiano, who has more than 20 years of experience across the spectrum of human resources disciplines, served as Senior Vice President of Human Resources and a member of the executive team for Thermo Fisher Scientific. "Elizabeth is a great addition to the AMAG leadership team," said William Heiden, President and CEO of AMAG. "Her proven ability to translate corporate strategy into an effective workforce and organizational plan will be highly valuable to us as we expand our business and migrate to a multi-product specialty pharmaceutical company." The Full Research Report on AMAG Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Array BioPharma Inc. Research Report
On January 3, 2014, Array BioPharma Inc. (Array BioPharma) announced its participation at the upcoming Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel in San Francisco, California. According to the Company, its CEO Ron Squarer will speak at the conference on January 14, 2014 at 4:00 p.m. PT. The Full Research Report on Array BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports